Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
Peripheral Kappa Opioid Receptor Signaling Takes on a Central Role - ScienceDirect
Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation | Scientific Reports
Biased signaling by endogenous opioid peptides | PNAS
Dynorphin/kappa-opioid receptor control of dopamine dynamics: Implications for negative affective states and psychiatric disorders - ScienceDirect
A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect
Frontiers | Heteromerization Modulates mu Opioid Receptor Functional Properties in vivo
Figure 2 from Development of κ opioid receptor antagonists. | Semantic Scholar
Neurophysiological process - Kappa-type opioid receptor in transmission of nerve impulses Pathway Map - PrimePCR | Life Science | Bio-Rad
Ligand and G-protein selectivity in the κ-opioid receptor | Nature
Frontiers | Opioid Receptor-Mediated Regulation of Neurotransmission in the Brain
Opioid receptor subtypes: fact or artifact? - British Journal of Anaesthesia
κ-opioid receptor - Wikipedia
Opioids in cancer: The κ‑opioid receptor (Review)
Table 1 from Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. | Semantic Scholar
Molecular mechanism of biased signaling at the kappa opioid receptor | Nature Communications
IJMS | Free Full-Text | αN-Acetyl β-Endorphin Is an Endogenous Ligand of σ1Rs That Regulates Mu-Opioid Receptor Signaling by Exchanging G Proteins for σ2Rs in σ1R Oligomers
Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor | Journal of Medicinal Chemistry
opioid receptor (English) - Medical terminology for medical students - - YouTube
Opioid receptor - Wikipedia
Opioid receptors | Introduction | BPS/IUPHAR Guide to PHARMACOLOGY
The Role of Mu-Opioids for Reward and Threat Processing in Humans: Bridging the Gap from Preclinical to Clinical Opioid Drug Studies | Current Addiction Reports